ROSATOM plans to begin this year the commercial sale of microsources of the radioisotope Iodine-125 for its use in the treatment of prostate cancer, according to the annual report of JSC Atomenergoprom, the state-owned holding company that unites Russia's civilian nuclear industry. 
The isotope is produced by the Research Institute of Atomic Reactors in Dimitrovgrad, while microsources of the isotope are produced at the Leypunsky Institute of Physics and Power Engineering in Obninsk.

Source: World Nuclear News